Skip to main content
SpringerLink
Log in

Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The emergence of fluoroquinolone-resistant gram-negative organisms has been demonstrated in patients given fluoroquinolone prophylaxis. To prevent increases in resistant bacteria, we restricted prophylactic use of fluoroquinolones. The spectrum and susceptibility patterns of isolates causing bloodstream infection (BSI) were assessed in patients receiving chemotherapy during periods of routine prophylaxis (period A: October 2001 to May 2003) and restricted prophylaxis (period B: June 2003 to January 2005). The total number of patients receiving chemotherapy was 442 during period A and 365 during period B. No significant differences were seen between periods with respect to patient characteristics. BSI was identified in 42 patients (44 episodes) during period A and 69 patients (74 episodes) during period B. Incidence of BSI increased significantly from 10.0% (44/442) during period A to 20.3% (74/365) during period B (P < 0.0001). Rate of Enterobacteriaceae BSI increased significantly, from 2.0% (9/442) during period A to 8.2% (30/365) during period B (P < 0.0001). For all BSI episodes, the proportion of BSI with gram-positive cocci decreased from 63.6% (28/44) during period A to 44.6% (33/74) during period B (P = 0.045), while the proportion of BSI with Enterobacteriaceae increased from 20.5% (9/44) to 40.5% (30/74) (P < 0.0001). The proportion of fluoroquinolone-resistant Enterobacteriaceae BSI for all Enterobacteriaceae BSI decreased from 75% (9/12) during period A to 17% (5/30) during period B (P = 0.0078). Restriction of fluoroquinolone prophylaxis affects the etiology of BSI and reduces the proportion of drug-resistant organisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D (1997) Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer—is it justified? Clin Infect Dis 25:346–348

    PubMed  CAS  Google Scholar 

  2. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1995) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805

    Google Scholar 

  3. Engels EA, Lau J, Barza M (1999) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179–87

    Google Scholar 

  4. Klastersky J (1996) Prevention of infection in neutropenic cancer patients. Curr Opin Oncol 8:270–278

    PubMed  CAS  Google Scholar 

  5. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987

    Article  PubMed  CAS  Google Scholar 

  6. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/− Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998

    Article  PubMed  CAS  Google Scholar 

  7. van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN (2005) Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 41:1372–1382

    Article  PubMed  CAS  Google Scholar 

  8. Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995

    PubMed  Google Scholar 

  9. Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, von Baum H (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40:1087–1093

    Article  PubMed  CAS  Google Scholar 

  10. Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330: 1240–1241

    Article  PubMed  CAS  Google Scholar 

  11. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have receiving prophylactic norfloxacin. Clin Infect Dis 20:557–560

    PubMed  CAS  Google Scholar 

  12. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687

    PubMed  CAS  Google Scholar 

  13. Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494

    Article  PubMed  CAS  Google Scholar 

  14. Baum HV, Franz U, Geiss HK (2000) Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 28:278–281

    Article  PubMed  CAS  Google Scholar 

  15. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551–575

    Article  PubMed  CAS  Google Scholar 

  16. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751

    Article  PubMed  Google Scholar 

  17. Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene LN, Ito JI, King E, Marcucci G, Montoya JG, Morris A, Noskin G, Rolston K, Schott AF, Segal B, Talcott JA (2004) Fever and neutropania. J National Comprehensive Cancer Network 23:390–432

  18. Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 39(Suppl 1):S11–14

    Article  PubMed  Google Scholar 

  19. National Committee for Clinical Laboratory Standards (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS approved standard M7–A5. National Committee for Clinical Laboratory Standards, Wayne

    Google Scholar 

  20. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1998) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140

    Article  Google Scholar 

  21. National Cancer Institute (2006) Cancer therapy evaluation program: common terminology criteria for adverse events version 3.0 (CTC). http://ctep.cancer.gov/forms/

  22. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051

    PubMed  CAS  Google Scholar 

  23. Vincent AL, Price R, Field T, Greene JN, Sandin RL (2005) Addition of fluoroquinolone prophylaxis to a blood and marrow transplant unit reduces gram-negative infections. Cancer Control 12:203–206

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infection Control and Prevention, Kyoto University Hospital, 54 Kawahara-cho, Shougoin, Sakyo-ku, Kyoto, 606-8507, Japan

    T. Saito, Y. Iinuma, S. Takakura, N. Fujihara & S. Ichiyama

  2. Department of Hematology/Oncology, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan

    S. Yoshioka, T. Ichinohe, T. Ishikawa & T. Uchiyama

Authors
  1. T. Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Iinuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Takakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Fujihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Ichinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Uchiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Ichiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Saito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saito, T., Yoshioka, S., Iinuma, Y. et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit. Eur J Clin Microbiol Infect Dis 27, 209–216 (2008). https://doi.org/10.1007/s10096-007-0428-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-007-0428-8

Keywords

Search

Navigation